Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin

A. Obr, P. Röselová, D. Grebeňová, K. Kuželová,

. 2014 ; 9 (9) : e107367. [pub] 20140908

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000635

Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000635
003      
CZ-PrNML
005      
20200120154727.0
007      
ta
008      
160108s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0107367 $2 doi
035    __
$a (PubMed)25198091
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Obr, Adam $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
245    10
$a Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin / $c A. Obr, P. Röselová, D. Grebeňová, K. Kuželová,
520    9_
$a Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a buněčná adheze $x účinky léků $7 D002448
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a dasatinib $x farmakologie $7 D000069439
650    _2
$a fibronektiny $x metabolismus $7 D005353
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x farmakologie $7 D000068877
650    _2
$a kinetika $7 D007700
650    _2
$a chronická myeloidní leukemie $x patologie $7 D015464
650    _2
$a fosforylace $x účinky léků $7 D010766
650    _2
$a transport proteinů $x účinky léků $7 D021381
650    _2
$a skupina kinas odvozených od src-genu $x metabolismus $7 D019061
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Röselová, Pavla $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Grebeňová, Dana $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Kuželová, Kateřina $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 9 (2014), s. e107367
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25198091 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200120155103 $b ABA008
999    __
$a ok $b bmc $g 1102916 $s 924841
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 9 $d e107367 $e 20140908 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...